Imperial Innovations Group, the listed technology commercialisation and investment company, and The Capital Fund, $100 million Regional Venture Capital Fund for London, have co-invested invested more than $1 million in NanoBioDesign Ltd., a company developing a range of toxicity screening systems to speed up the drug discovery process.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.